Gao Yue, Feng Yadong, Chang Yanyan, Zhu Zhu, Zhao Huanxi, Xu Wei, Zhao Mengya, Xiao Yusheng, Tian Lu, Xiu Yang
Changchun University of Chinese Medicine, Changchun 130117, P. R. China.
ACS Omega. 2024 May 16;9(21):22744-22753. doi: 10.1021/acsomega.4c00837. eCollection 2024 May 28.
The biotransformation of ginsenosides using microorganisms represents a promising and ecofriendly approach for the production of rare ginsenosides. The present study reports on the biotransformation of ginsenoside Rb1 using the fungus , resulting in the production of ginsenoside Rd and seven rare ginsenosides with novel structures. Employing high-performance liquid chromatography coupled with high-resolution tandem mass spectrometry, the identities of the transformation products were rapidly determined. Two sets of isomers with molecular weights of 980.56 and 962.55 were discovered among the seven rare ginsenosides, which were generated through the isomerization of the olefin chain in the protopanaxadiol (PPD)-type ginsenoside skeleton. Each isomer exhibited characteristic fragment ions and neutral loss patterns in their tandem mass spectra, providing evidence of their unique structures. Time-course experiments demonstrated that the transformation reaction reached equilibrium after 14 days, with Rb1 initially generating Rd and compound , followed by the formation of other rare ginsenosides. The biotransformation process catalyzed by was found to involve not only the typical deglycosylation reaction at the C-20 position but also hydroxylation at the C-22 and C-23 positions, as well as hydrogenation, transfer, and cyclization of the double bond at the C-24(25) position. These enzymatic capabilities extend to the structural modification of other PPD-type ginsenosides such as Rc and Rd, revealing the potential of for the production of a wider range of rare ginsenosides. The transformation activities observed in are unprecedented among fungal biotransformations of ginsenosides. This study highlights the application of a medicinal fungi-based biotransformation strategy for the generation of rare ginsenosides with enhanced structural diversity, thereby expanding the variety of bioactive compounds derived from ginseng.
利用微生物对人参皂苷进行生物转化是一种生产稀有人参皂苷的有前景且环保的方法。本研究报道了利用真菌对人参皂苷Rb1进行生物转化,从而产生了人参皂苷Rd和七种具有新结构的稀有人参皂苷。采用高效液相色谱与高分辨率串联质谱联用技术,快速确定了转化产物的身份。在七种稀有人参皂苷中发现了两组分子量分别为980.56和962.55的异构体,它们是通过原人参二醇(PPD)型人参皂苷骨架中烯烃链的异构化产生的。每种异构体在其串联质谱中均表现出特征性的碎片离子和中性丢失模式,为其独特结构提供了证据。时间进程实验表明,转化反应在14天后达到平衡,Rb1最初生成Rd和化合物,随后形成其他稀有人参皂苷。发现由该真菌催化的生物转化过程不仅涉及C-20位的典型去糖基化反应,还涉及C-22和C-23位的羟基化,以及C-24(25)位双键的氢化、转移和环化。这些酶促能力扩展到其他PPD型人参皂苷如Rc和Rd的结构修饰,揭示了该真菌在生产更广泛的稀有人参皂苷方面的潜力。在人参皂苷的真菌生物转化中观察到的这种转化活性是前所未有的。本研究强调了基于药用真菌的生物转化策略在生成结构多样性增强的稀有人参皂苷方面的应用,从而扩大了源自人参的生物活性化合物的种类。